In patients with well-differentiated (WD) neuroendocrine tumors (NET), long-acting octreotide (LAR), conventionally administered at a dose of 30 mg every 28 days, has well-documented anti-secretive but limited antiproliferative effects.
Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses / Ferolla, P; Faggiano, A; Grimaldi, F; Ferone, D; Scarpelli, G; Ramundo, V; Severino, R; Bellucci, M C; Camera, L M; Lombardi, G; Angeletti, G; Colao, A. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 1720-8386. - 35:3(2012), pp. 326-331. [10.3275/7869]
Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses
Faggiano, A;Ramundo, V;
2012
Abstract
In patients with well-differentiated (WD) neuroendocrine tumors (NET), long-acting octreotide (LAR), conventionally administered at a dose of 30 mg every 28 days, has well-documented anti-secretive but limited antiproliferative effects.| File | Dimensione | Formato | |
|---|---|---|---|
|
Ferolla_Long-acting-octreotide_2012.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
155.64 kB
Formato
Adobe PDF
|
155.64 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
